Inhibition of protein kinase CK2 leads to a modulation of androgen receptor dependent transcription in prostate cancer cells

Prostate

Volumn 67, Issue 2, 2007, Pages 125-134

  Götz, Claudia ^a   Bachmann, Christa ^a   Montenarh, Mathias ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Emodin; Kinase inactive mutants; Prostate specific antigen PSA; Reporter assays; TBB

Indexed keywords

ANDROGEN RECEPTOR; BENZOTRIAZOLE DERIVATIVE; CASEIN KINASE II; EMODIN; TETRABROMOBENZOTRIAZOLE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; REPORTER GENE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

ADENOCARCINOMA; BENZIMIDAZOLES; BLOTTING, WESTERN; CASEIN KINASE II; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; EMODIN; GENES, REPORTER; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTORS, ANDROGEN; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 33846583525     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20471     Document Type: Article

References (39)

1. Quigley CA, De BA, Marschke KB, el-Awady MK, Wilson EM, French FS. Androgen receptor defects: Historical, clinical, and molecular perspectives. Endocr Rev 1995;16:271-321.
2. Smith DF. Dynamics of heat shock protein 90-progesterone receptor binding and the disactivation loop model for steroid receptor complexes. Mol Endocrinol 1993;7:1418-1429.
3. Brinkmann AO, Blok LJ, de Ruiter PE, Doesburg P, Steketee K, Berrevoets CA, Trapman J. Mechanisms of androgen receptor activation and function. J Steroid Biochem Mol Biol 1999;69:307-313.
4. Riegman PH, Vlietstra RJ, van der Korput JA, Brinkmann AO, Trapman J. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol 1991;5:1921-1930.
5. Yang F, Li X, Sharma M, Sasaki CY, Longo DL, Lim B, Sun Z. Linking beta-catenin to androgen-signaling pathway. J Biol Chem 2002;277:11336-11344.
6. Gao X, Porter AT, Honn KV. Tumor suppressor genes and their involvment in human prostate cancer. Cancer Molec Biol 1995;2:475-498.
7. Eder IE, Culig Z, Ramoner R, Thurnher M, Putz T, Nessler-Menardi C, Tiefenthaler M, Bartsch G, Klocker H. Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Ther 2000;7:997-1007.
8. Geiger T, Muller M, Monia BP, Fabbro D. Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice. Clin Cancer Res 1997;3:1179-1185.
9. Yim H, Lee YH, Lee CH, Lee SK. Emodin, an anthraquinone derivative isolated from the rhizomes of Rheum palmatum, selectively inhibits the activity of casein kinase II as a competitive inhibitor. Planta Med 1999;65:9-13.
10. Sarno S, Reddy H, Meggio F, Ruzzene M, Davies SP, Donella-Deana A, Shugar D, Pinna LA. Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ('casein kinase-2'). FEBS Letters 2001;496:44-48.
11. Litchfield DW. Protein kinase CK2: Structure, regulation and role in cellular decisions of life and death. Biochem J 2003;369:1-15.
12. Allende JE, Allende CC. Protein kinase CK2: An enzyme with multiple substrates and puzzling regulation. FASEB J 1995;9:313-323.
13. Meggio F, Pinna LA. One-thousand-and-one substrates of protein kinase CK2? The FASEB J 2003;17:349-368.
14. Blanquet PR. Casein kinase 2 as a potentially important enzyme in the nervous system. Prog Neurobiol 2000;60:211-246.
15. Padmanabha R, Chen-Wu JLP, Hanna DE, Glover CVC. Isolation, sequencing and disruption of the yeast CKA2 gene: Casein kinase II is essential for viability in Saccharomyces cerevisiae. Mol Cell Biol 1990;10:4089-4099.
16. Pepperkok R, Lorenz P, Ansorge W, Pyerin W. Casein kinase II is required for transition of G0/G1, early G1, and G1/S phases of the cell cycle. J Biol Chem 1994;269:6986-6991.
17. Turenne GA, Paul P, Laflair L, Price BD. Activation of p53 transcriptional activity requires ATM's kinase domain and multiple N-terminal serine residues of p53. Oncogene 2001;20:5100-5110.
18. Ahmed K, Davis AT, Wang HM, Faust RA, Yu SH, Tawfic S. Significance of protein kinase CK2 nuclear signaling in neoplasia. J Cell Biochem 2000; 130-135.
19. Faust RA, Gapany M, Tristani P, Davis A, Adams GL, Ahmed K. Elevated protein kinase CK2 activity in chromatin of head and neck tumors: Association with malignant transformation. Cancer Lett 1996;101:31-35.
20. Landesman-Bollag E, Channavajhala PL, Cardiff RD, Seldin DC. p53 deficiency and misexpression of protein kinase CK2α collaborate in the development of thymic lymphomas in mice. Oncogene 1998;16:2965-2974.
21. Guo CH, Yu SH, Davis AT, Wang HM, Green JE, Ahmed K. A potential role of nuclear matrix-associated protein kinase CK2 in protection against drug-induced apoptosis in cancer cells. J Biol Chem 2001;276:5992-5999.
22. Ruzzene M, Penzo D, Pinna LA. Protein kinase CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells. Biochem J 2002;364:41-47.
23. Krippner-Heidenreich A, Talanian RV, Sekul R, Kraft R, Thole H, Ottleben H, Luscher B. Targeting of the transcription factor Max during apoptosis: Phosphorylation-regulated cleavage by caspase-5 at an unusual glutamic acid residue in position P1. Biochem J 2001;358:705-715.
24. Goueli SA, Holtzman JL, Ahmed K. Phosphorylation of the androgen receptor by a nuclear cAMP-independent protein kinase. Biochem Biophys Res Commun 1984;123:778-784.
25. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43:1809-1818.
26. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T 4. Nature 1970;227:680-682.
27. Faust M, Schuster N, Montenarh M. Specific binding of protein kinase CK2 catalytic subunits to tubulin. FEBS Lett 1999;462:51-56.
28. Nastainczyk W, Schmidt-Spaniol I, Boldyreff B, Issinger O-G. Isolation and characterization of a monoclonal anti-protein kinase CK2 β-subunit antibody of the IgG class for the direct detection of CK2 β-subunit in tissue cultures of various mammalian species and human tumors. Hybridoma 1995;14:335-339.
29. Kuenzel EA, Krebs EG. A synthetic peptide substrate specific for casein kinase II. Proc Natl Acad Sci USA 1985;82:737-741.
30. Cleutjens KB, van Eekelen CC, van der Korput HA, Brinkmann AO, Trapman J. Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol Chem 1996;271:6379-6388.
31. Penner CG, Wang ZL, Litchfield DW. Expression and localization of epitope-tagged protein kinase CK2. J Cell Biochem 1997;64:525-537.
32. Gioeli D, Ficarro SB, Kwiek JJ, Aaronson D, Hancock M, Catling AD, White FM, Christian RE, Settlage RE, Shabanowitz J, Hunt DF, Weber MJ. Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem 2002;277:29304-29314.
33. Zhou ZX, Kemppainen JA, Wilson EM. Identification of three proline-directed phosphorylation sites in the human androgen receptor. Mol Endocrinol 1995;9:605-615.
34. Janne OA, Palvimo JJ, Kallio P, Mehto M. Androgen receptor and mechanism of androgen action. Ann Med 1993;25:83-89.
35. Miyata Y, Yahara I. The 90-kDa heat shock protein, HSP90, binds and protects casein kinase II from self-aggregation and enhances its kinase activity. J Biol Chem 2002;267:7042-7047.
36. Miyata Y, Chambraud B, Radanyi C, Leclerc J, Lebeau MC, Renoir JM, Shirai R, Catelli MG, Yahara I, Baulieu EE. Phosphorylation of the immunosuppressant FK506-binding protein FKBP52 by casein kinase II: Regulation of HSP90-binding activity of FKBP52. Proc Natl Acad Sci USA 1997;94:14500-14505.
37. Song DH, Dominguez I, Mizuno J, Kaut M, Mohr SC, Seldin DC. CK2 phosphorylation of the armadillo repeat region of β-catenin potentiates Wnt signaling. J Biol Chem 2003;278:24018-24025.
38. Cha TL, Qiu L, Chen CT, Wen Y, Hung MC. Emodin downregulates androgen receptor and inhibits prostate cancer cell growth. Cancer Res 2005;65:2287-2295.
39. Hessenauer A, Montenarh M, Götz C. CK2-mediated pathways are interrupted in hormone-refractory prostate carcinoma cell lines. Int J Oncol 2003;22:1263-1270.